Patents by Inventor Klaus Peter Hertel

Klaus Peter Hertel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for treating cognitive deficits
    Publication number: 20110207744
    Abstract: The invention relates to methods of treating cognitive dysfunction and improving cognitive functioning comprising the administration of trans-4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine or a pharmaceutically acceptable salt thereof to a patient in need thereof. Moreover the invention relates to an improved binder in a composition comprising 4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine.
    Type: Application
    Filed: May 5, 2011
    Publication date: August 25, 2011
    Applicant: H. Lundbeck A/S
    Inventors: Christina Kurre Olsen, Rene Holm, Christine Kau, Birgitte Willumsen, Klaus Peter Hertel, Lone Bruun, Karina Krojer Soby
  • Oral Formulation
    Publication number: 20110178094
    Abstract: The invention relates to a pharmaceutical composition intended for oral administration comprising low doses of 4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and to a composition comprising the compound.
    Type: Application
    Filed: October 1, 2009
    Publication date: July 21, 2011
    Applicant: H. LUNDBECK A/S
    Inventors: Rene Holm, Christine Kau, Birgitte Willumsen, Klaus Peter Hertel, Christina Kurre Olsen, Lone Bruun, Karina Krojer Soby
  • USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED
    Publication number: 20100256145
    Abstract: The invention relates, inter alia, to a method for reducing symptoms of, or for treating, one or more disorders or conditions wherein the dopaminergic system is disrupted, the method comprising administering to a host in need thereof an effective amount of a compound that is able to increase the ion flow through KCNQ potassium channels.
    Type: Application
    Filed: July 31, 2008
    Publication date: October 7, 2010
    Applicant: H. LUNDBECK A/S
    Inventors: Henriette Husum Bak-Jensen, Klaus Peter Hertel
  • METHOD FOR TREATING COGNITIVE DEFICITS
    Publication number: 20090306092
    Abstract: The invention relates to methods of treating cognitive dysfunction and improving cognitive functioning comprising the administration of trans-4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine or a pharmaceutically acceptable salt thereof to a patient in need thereof. Moreover the invention relates to an improved binder in a composition comprising 4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine.
    Type: Application
    Filed: May 7, 2009
    Publication date: December 10, 2009
    Applicant: H. Lundbeck A/S
    Inventors: Christina Kurre Olsen, Rene Holm, Christine Kau, Birgitte Willumsen, Klaus peter Hertel, Lone Bruun, Karina Krojer Soby
  • Treatment of ADHD
    Patent number: 7294638
    Abstract: The use of 3-[1-[2-(1-acetyl-2,3-dihydro-1H-indol-3-yl)ethyl]-1,2,3,6-tetrahydropyridin-4-yl]-6-chloro-1H-indole, any of its enantiomers and pharmaceutically acceptable salts thereof for the preparation of a pharmaceutical composition for the treatment of attention deficit hyperactivity disorder.
    Type: Grant
    Filed: May 7, 2002
    Date of Patent: November 13, 2007
    Assignee: H. Lundbeck A/S
    Inventors: Klaus Peter Hertel, Jorn Arnt
  • Treatment of adhd
    Publication number: 20040152737
    Abstract: The use of 3-[1-[2-(1-acetyl-2,3-dihydro-1H-indol-3-yl)ethyl]-1,2,3,6-tetrahydropyridin-4-yl]-6-chloro-1H-indole, any of its enantiomers and pharmaceutically acceptable salts thereof for the preparation of a pharmaceutical composition for the treatment of attention deficit hyperactivity disorder.
    Type: Application
    Filed: November 7, 2003
    Publication date: August 5, 2004
    Inventors: Klaus Peter Hertel, Jorn Arnt